India, Sweden and The Netherlands form HIV/AIDS research partnership
A first-of-its-kind collaboration has been announced by the governments of India, Sweden and The Netherlands with the goal of advancing research in the treatment of HIV and AIDS by leveraging the “complementary research strengths and diverse expertise” of the three nations.
Principally, the collaboration will concern itself with the pursuit of better and more effective tools to understand and address the virus on a global scale, and well as tackling major obstacles such as drug resistance, viral diversity, coinfections and comorbidities. The tools will allow for better preventative and treatment methods, and even the possibility of a cure for the virus in the long-term.
To this end, the project will examine relevant populations of research interest and harness cutting-edge clinical technology and predictive analytics to better understand the geographic diversity and different clades of the virus, while also seeking to investigate divergent human immune responses as determined by varied genetic, immunological and behavioural characteristics.
A number of governmental, non-governmental and research institutions, including India’s Department of Biotechnology, National AIDS Control Organization and International AIDS Vaccine Initiative, the Indian Institute of Science, Institute of Genomics and Integrative Biology, Institute of Bioinformatics, Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), and Y R Gaitonde Centre for AIDS Research and Education, as well as The Netherlands Erasmus Medical Centre and Sweden’s Karolinska Institute.
More details on the partnership are due to revealed shortly in a media address by Bruno Bruins, Minister for Medical Care, Government of the Netherlands and Dr Renu Swarup, Secretary, Department of Biotechnology, Government of India.
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …